The Oncology Institute (TOI)
(Delayed Data from NSDQ)
$0.32 USD
-0.01 (-3.10%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.32 0.00 (1.30%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.32 USD
-0.01 (-3.10%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.32 0.00 (1.30%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Oncology Institute, Inc. (TOI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Oncology Institute (TOI) delivered earnings and revenue surprises of -70% and 4.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 27.27% and 5.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics (SERA) delivered earnings and revenue surprises of -8.70% and 70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Enhabit (EHAB) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Enhabit (EHAB) delivered earnings and revenue surprises of 16.67% and 2.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ascend Wellness Holdings, Inc. (AAWH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -25% and 2.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
The Oncology Institute (TOI) delivered earnings and revenue surprises of -83.33% and 0.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of -1.47% and 2.12%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Down -23.64% in 4 Weeks, Here's Why The Oncology Institute (TOI) Looks Ripe for a Turnaround
by Zacks Equity Research
The Oncology Institute (TOI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Beat the Market Like Zacks: UnitedHealth, Casey's, Cencora in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Elevance Health (ELV) Q3 Earnings Top Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 6.39% and 0.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?